Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Hematology

Understanding Your Risk: Clots vs. Long-Term Progression

At a Glance

In Polycythemia Vera (PV), your risk category primarily predicts your likelihood of a blood clot rather than life expectancy. Risk is based on your age and clot history. Your care team will monitor your blood counts and symptoms to prevent clots and watch for slow, long-term progression.

When you hear the term “risk” in the context of Polycythemia Vera (PV), it is important to understand exactly what your doctor is measuring. In PV, risk stratification is primarily used to predict the likelihood of a thrombotic event (a blood clot) rather than your overall life expectancy [1][2].

Because PV is a chronic condition that you may live with for decades, doctors use these categories to determine how aggressive your treatment needs to be to keep you safe [3][4].

The Two Tiers of Thrombosis Risk

For many years, the standard way to group PV patients has been based on two simple factors: your age and your medical history [2][5].

  • Low Risk: You are age 60 or younger AND you have never had a major blood clot (like a stroke, heart attack, or deep vein thrombosis) [2][3].
  • High Risk: You are over age 60 OR you have a history of a major blood clot [2][3].

If you are “High Risk,” your doctor will almost certainly recommend medication (cytoreductive therapy) to lower your blood counts [2]. If you are “Low Risk,” you may only need phlebotomy and aspirin, though this can change if other risk factors appear [2][6].

Hidden Risk Factors: White Blood Cells

While the focus is often on red blood cells, your White Blood Cell (WBC) count also plays a role in your risk [7]. Recent research has shown that a high WBC count (leukocytosis) is an independent risk factor for blood clots [7][8]. This means that even if your hematocrit is perfectly controlled at 45%, having high white blood cells can still make your blood more “reactive” and prone to clotting [7]. Because of this, modern management aims to normalize your entire blood count, not just the red cells [9][8].

Looking Down the Road: Disease Progression

One of the most common questions for newly diagnosed patients is: “Will this turn into leukemia?” While the risk exists, it is important to keep the timeline in perspective. PV is a slow-moving disease [4].

Post-PV Myelofibrosis (PPV-MF)

Over time, the bone marrow may begin to develop scarring, a phase called myelofibrosis. This is a progressive change that happens in about 25% of patients after 20 years of living with PV [4][10]. Doctors monitor for this by checking your spleen size and looking for signs of anemia (low red blood cells) on your blood tests [10][11].

Acute Myeloid Leukemia (AML)

The transformation into an aggressive “acute” leukemia is less common and typically happens much later in the disease course [12]. This risk increases slightly with age and the length of time you have had the disease [12][13].

Empowered Monitoring

The best way to manage these long-term risks is through consistent, proactive monitoring. You are not a passive observer of this disease; by working with your care team, you can stay ahead of changes [14]. Standard monitoring includes:

  • Regular Blood Counts: Tracking your HCT, WBC, and platelets [14].
  • Symptom Tracking: Reporting new fatigue, night sweats, or abdominal pain [15].
  • Physical Exams: Having your doctor check for an enlarged spleen [11].
  • Molecular Checks: Occasionally re-evaluating your JAK2 allele burden to see if the “clone” of PV cells is growing or shrinking [16][17].

Understanding your risk isn’t about fearing the future—it’s about having the right information to protect your health today [1].

Common questions in this guide

What makes someone high risk in Polycythemia Vera?
In Polycythemia Vera, you are considered high risk if you are over the age of 60 or if you have a history of a major blood clot. This classification helps your doctor determine if you need specific medications to lower your blood cell counts.
Do high white blood cells matter if my red blood cells are under control?
Yes, having a high white blood cell count is an independent risk factor for blood clots. Modern treatments aim to normalize all of your blood counts, including white blood cells, to help lower your overall risk of clotting.
Will my Polycythemia Vera turn into leukemia or myelofibrosis?
Polycythemia Vera is a very slow-moving disease. About 25% of patients may develop scarring in the bone marrow, called myelofibrosis, after living with the condition for 20 years. Transformation into acute myeloid leukemia is much less common and usually happens later in the disease course.
How will my doctor monitor my disease for long-term progression?
Your care team will track your condition through regular blood tests to check your cell counts, physical exams to monitor your spleen size, and symptom tracking. They may also occasionally use molecular tests to check your JAK2 mutation levels.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which risk category do I fall into, and is my treatment focused more on preventing clots or preventing disease progression?
  2. 2.How has my white blood cell count been trending lately, and does that change my risk for a blood clot?
  3. 3.If I am in the 'low risk' group now, what changes would move me into the 'high risk' group?
  4. 4.How often should we be checking the size of my spleen to monitor for changes?
  5. 5.What is the likelihood of my PV transforming into myelofibrosis in the next 10 or 15 years?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Polycythemia and Thrombocytosis.

    Parnes A, Ravi A

    Primary care 2016; (43(4)):589-605 doi:10.1016/j.pop.2016.07.011.

    PMID: 27866579
  2. 2

    NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.

    Mesa RA, Jamieson C, Bhatia R, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2017; (15(10)):1193-1207.

    PMID: 28982745
  3. 3

    Clinical characteristics of Japanese patients with polycythemia vera: results of the JSH-MPN-R18 study.

    Edahiro Y, Ito T, Gotoh A, et al.

    International journal of hematology 2022; (116(5)):696-711 doi:10.1007/s12185-022-03412-x.

    PMID: 35809214
  4. 4

    Rapid progression of myelofibrosis in polycythemia vera patient carrying SRSF2 c.284C>A p.(Pro95His) and unique ASXL1 splice site c.1720-2A>G variant.

    Kanduła Z, Kroll-Balcerzak R, Lewandowski K

    Journal of clinical laboratory analysis 2022; (36(5)):e24388 doi:10.1002/jcla.24388.

    PMID: 35435261
  5. 5

    A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: A British Society for Haematology Guideline.

    McMullin MFF, Mead AJ, Ali S, et al.

    British journal of haematology 2019; (184(2)):161-175 doi:10.1111/bjh.15647.

    PMID: 30426472
  6. 6

    How I treat polycythemia vera.

    Spivak JL

    Blood 2019; (134(4)):341-352 doi:10.1182/blood.2018834044.

    PMID: 31151982
  7. 7

    Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL.

    Gerds AT, Mesa R, Burke JM, et al.

    Blood 2024; (143(16)):1646-1655 doi:10.1182/blood.2023020232.

    PMID: 38142448
  8. 8

    Elevated White Blood Cell Levels and Thrombotic Events in Patients With Polycythemia Vera: A Real-World Analysis of Veterans Health Administration Data.

    Parasuraman S, Yu J, Paranagama D, et al.

    Clinical lymphoma, myeloma & leukemia 2020; (20(2)):63-69 doi:10.1016/j.clml.2019.11.010.

    PMID: 31865003
  9. 9

    Diagnosis and Management of Cardiovascular Risk in Patients with Polycythemia Vera.

    Benevolo G, Marchetti M, Melchio R, et al.

    Vascular health and risk management 2023; (19()):765-778 doi:10.2147/VHRM.S429995.

    PMID: 38025519
  10. 10

    Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management.

    Tefferi A, Barbui T

    American journal of hematology 2023; (98(9)):1465-1487 doi:10.1002/ajh.27002.

    PMID: 37357958
  11. 11

    The assessment of health-related quality of life in patients with polycythemia vera.

    Doğan EE, Keklik Karadağ F, Aydin D, et al.

    Medicine 2024; (103(30)):e38814 doi:10.1097/MD.0000000000038814.

    PMID: 39058813
  12. 12

    Risk of Transformation to Acute Myeloid Leukaemia and Myelodysplastic Syndromes in Patients With Myeloproliferative Neoplasms Over Attained Age and Time Since Diagnosis: A Nationwide Cohort Study.

    Batyrbekova N, Landtblom AR, Hultcrantz M, et al.

    European journal of haematology 2026; (116(6)):850-862 doi:10.1111/ejh.70141.

    PMID: 41717866
  13. 13

    No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials.

    Barbui T, Carobbio A, Ghirardi A, et al.

    Haematologica 2017; (102(6)):e219-e221 doi:10.3324/haematol.2017.165126.

    PMID: 28255021
  14. 14

    Polycythemia Vera (PV): Update on Emerging Treatment Options.

    Benevolo G, Vassallo F, Urbino I, Giai V

    Therapeutics and clinical risk management 2021; (17()):209-221 doi:10.2147/TCRM.S213020.

    PMID: 33758507
  15. 15

    Polycythemia vera: diagnosis, clinical course, and current management

    Büyükaşik Y, Alİ R, Ar C, et al.

    Turkish journal of medical sciences 2018; (48(4)):698-710 doi:10.3906/sag-1806-43.

    PMID: 30114348
  16. 16

    JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome.

    Kanduła Z, Janowski M, Więckowska B, et al.

    Journal of cancer research and clinical oncology 2023; (149(8)):4789-4803 doi:10.1007/s00432-022-04327-0.

    PMID: 36242602
  17. 17

    A higher JAK2V617F allele burden may be a risk factor for hemorrhagic events in younger patients with polycythemia vera.

    Furuya C, Hashimoto Y, Morishita S, et al.

    Hematology (Amsterdam, Netherlands) 2024; (29(1)):2427905 doi:10.1080/16078454.2024.2427905.

    PMID: 39545588

This page provides educational information about Polycythemia Vera risk categories and disease progression. It is not medical advice. Always discuss your specific risk factors, test results, and treatment plan with your hematologist.

Get notified when new evidence is published on Polycythemia vera.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.